All articles by Staff Writer
Staff Writer
Microbix Achieves Essential EU Regulatory Accreditations
IVDR Compliance and CE Certifications for REDx™ QAPs
MEDICA HEALTH IT FORUM: Success in mastering healthcare challenges through digital innovations!
From sustainable AI to future clinics – `Hospital of the Future´ addresses optimal clinical networking
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics. The instrument and accessories are 510(k) exempt in the U.S. and IVDR-certified for diagnostic use in Europe.
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples
PreAnalytiX GmbH, a joint venture between QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) and BD (Becton, Dickinson and Company; NYSE: BDX), today announced the launch of the PAXgene® Urine Liquid Biopsy Set, which enables the reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS). The new set will be commercialized by QIAGEN.
ADLM publishes new guidance on lipid testing to improve care for patients with cardiovascular disease
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) has issued expert guidance on lipid tests, which measure blood levels of fats and cholesterol to help assess a patient’s risk of heart disease and stroke. By giving clinicians and laboratory medicine professionals much-needed clarity on how to best use these tests, the new guidelines will ensure that more patients with cardiovascular disease get the treatment they need.
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital PCR (dPCR) platform QIAcuity for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring.
MEDICA LABMED FORUM 2024: international experts meet to discuss trending topics in laboratory medicine
“Lab 4.0”, shortage of skilled personnel, incentives for major disease complexes and a look ahead
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinhos is now able to launch an advanced PCR-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus (HCV and HBV), a capability previously unavailable in Brazil’s blood donation program. It also supports epidemiological surveillance of Brazil’s ongoing dengue epidemic by composing Bio-Manguinhos/Fiocruz dengue molecular kits based on unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz. QIAGEN will supply critical molecular biology technologies, custom solutions, and comprehensive training to facilitate Brazil’s public health initiative.
Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available
World’s first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii
Roche expands digital pathology with AI tools from eight new partners
Roche’s strategic collaborations with Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics, and Stratipath, will help pathologists and scientists in cancer research and diagnosis by leveraging advanced AI technology